To treat this blood system disease, TPO receptor agonist is approved for marketing

▎WuXi AppTec Content Team Editor Recently, a thrombopoietin (TPO) receptor agonist, roprostim for injection (previously known as romiprostim for injection), was approved by the State Drug Administration of China ( NMPA) approved for marketing for primary immune thrombocytopenia (ITP)
.

Screenshot source: NMPA official website Rare autoimmune disease Immune thrombocytopenia is a rare and severe autoimmune disease that belongs to the blood disease
.

In people with immune thrombocytopenia, their immune system attacks and destroys their own platelets, which play an active role in blood clotting and wound healing
.

Immune thrombocytopenia is characterized by low platelet counts in the blood and can lead to serious bleeding events or complications, and even death
.

The common symptoms of adult patients with immune thrombocytopenia are mainly repeated skin and mucous membrane bleeding, such as petechiae, purpura, ecchymosis, and difficult to stop bleeding after trauma; epistaxis, bleeding gums, and menorrhagia are also common; severe Visceral hemorrhage is relatively rare
.

At the same time, the condition of patients with immune thrombocytopenia may also suddenly worsen due to infection and other reasons, and extensive and severe skin, mucous membrane and visceral bleeding may occur
.

Fatigue is another common symptom of immune thrombocytopenia
.

In addition, excessive bleeding or prolonged menorrhagia can lead to hemorrhagic anemia
.

According to the data of the 9th edition of "Internal Medicine", the incidence of immune thrombocytopenia in Chinese adults is 5-10/100,000 people, and the incidence rate of male and female is similar; the incidence rate of women of childbearing age is higher than that of men; the elderly over 60 years old is the highest incidence rate population, the incidence is twice as high as those under the age of 60, and the risk of bleeding increases with age
.

Image source: 123RF Thrombopoietin Receptor Agonist At present, there is no cure or radical cure for immune thrombocytopenia.
The purpose of its first-line or second-line treatment is to increase the patient's platelet count to a safe level and reduce mortality
.

The first-line therapy for immune thrombocytopenia is the use of glucocorticoids or intravenous immune globulin; the second-line therapy mainly includes various immune preparations, thrombopoietin receptor agonists, and splenectomy
.

Roprostim is a recombinant protein that belongs to the thrombopoietin receptor agonist, and by binding to the thrombopoietin receptor, it can stimulate intracellular transcriptional pathways, resulting in increased platelet production
.

According to public information, roprostim is produced in Escherichia coli by recombinant DNA technology, which can simulate the effect of the human body's natural thrombopoietin, thereby increasing the platelet count
.

When roprestim enters the human body and binds to the thrombopoietin receptor, it promotes the growth of bone marrow megakaryocyte colony-forming units (CFU-Meg) and increases platelet production through the JAK2 and STAT5 kinase pathways
.

In addition, the mechanism of action of roprestim to stimulate platelet production by stimulating the thrombopoietin receptor is very different from commonly used drugs that increase platelet counts by inhibiting platelet destruction
.

In 2009, Ropstim was also selected as the "Best Biotechnology Product" by the Galen Award, known as the "Nobel Prize in Medicine"
.

Image source: 123RF At present, roprostim has been approved for marketing in dozens of countries and regions around the world, including the United States, the European Union, Canada, and Australia.
The approved indications include immune thrombocytopenia that is poorly treated by other drugs or surgery.
Symptomatic adult patients, pediatric patients 1 year of age and older with immune thrombocytopenia lasting at least 6 months and an inadequate response to corticosteroids, immunoglobulins, or splenectomy
.

We expect that with the approval of roprostim in China, it will benefit more Chinese patients with immune thrombocytopenia
.

Recommended reading The treatment of common pneumonia, the approval of new antibiotics for the marketing of fungal infectious diseases with a very high fatality rate, ushered in a new oral drug and another new drug approved in China, reducing the recurrence rate by more than 50% every year! The first-line treatment of non-small cell lung cancer can be done at home, and the new PD-L1 monoclonal antibody has been approved for marketing.
Another new cancer drug has been approved in China! This refractory tumor has a new choice of reference materials [1] China State Food and Drug Administration's January 11 Drug Approval Document Pending Information.
Retrieved Jan 12, 2022, from https:// zwfw/sdxx/sdxxyp/yppjfb/20220111154458197.
html[2]Nplate® (romiplostim) Now Approved For Earlier Use In Adults With Immune Thrombocytopenia.
Retrieved Jan 12, 2022, from http://investors.
amgen.
com/news-releases /news-release-details/nplater-romiplostim-now-approved-earlier-use-adults-immune[3] Ge Junbo, Xu Yongjian, Wang Chen.
Internal Medicine [M].
9th Edition.
Beijing: People's Health Publishing House, 2018 .
Disclaimer: The WuXi AppTec content team focuses on introducing global biomedical health research progress
.

This article is for information exchange purposes only, and the views expressed in this article do not represent WuXi AppTec's position, nor do they represent WuXi AppTec's support or opposition to the views expressed in this article
.

This article is also not a treatment plan recommendation
.

For guidance on treatment options, please visit a regular hospital
.